文献速递浆细胞疾病

HECA452识别的E-选择素配体诱导骨髓瘤耐药,E-选择素拮抗剂GMI-1271可逆转该耐药

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271.
PubMed 文献 · Leukemia · 2017-04-25

研究探讨E-选择素配体在多发性骨髓瘤(MM)生物学中的作用。功能性E-选择素配体仅见于少数MM细胞系,其扩增后与重组E-选择素体外特异性结合;相关基因mRNA升高与CoMMpass研究中较差的无进展生存相关。体内E-选择素配体富集细胞致病更强且对硼替佐米完全耐药,联用GMI-1271可逆转耐药;原发MM样本中配体阳性细胞在复发患者比例更高。

要点

  • E-选择素配体仅见于少数MM细胞系,扩增后与重组E-选择素体外特异性结合。
  • E-选择素配体富集细胞体内致病更强且对硼替佐米完全耐药,GMI-1271可逆转耐药。
  • 原发MM骨髓和外周血中存在配体阳性细胞,复发患者比例更高。

核心结论

  • 靶向E-选择素受体/配体相互作用可为克服MM转移和化疗耐药提供依据。

研究设计与样本

  • 研究采用MM细胞系、CoMMpass研究数据、体内模型及原发MM样本,评估E-选择素配体功能及其对硼替佐米敏感性的影响。

主要发现

  • 功能性E-选择素配体仅局限于少数MM细胞系,扩增后与重组E-选择素体外呈现特异且强烈的相互作用。
  • 参与E-选择素配体生成的基因mRNA水平升高与CoMMpass研究中较差的无进展生存相关。
  • 体内E-选择素配体富集细胞诱导更具侵袭性的疾病,且对硼替佐米完全不耐药。
  • 联用GMI-1271可逆转E-选择素配体富集细胞对硼替佐米的耐药。
  • 原发MM骨髓和外周血样本中存在E-选择素配体阳性细胞,复发患者中比例更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is characterized by the clonal expansion and metastatic spread of malignant plasma cells to multiple sites in the bone marrow (BM). Recently, we implicated the sialyltransferase ST3Gal-6, an enzyme critical to the generation of E-selectin ligands, in MM BM homing and resistance to therapy. Since E-selectin is constitutively expressed in the BM microvasculature, we wished to establish the contribution of E-selectin ligands to MM biology. We report that functional E-selectin ligands are restricted to a minor subpopulation of MM cell lines which, upon expansion, demonstrate specific and robust interaction with recombinant E-selectin in vitro. Moreover, an increase in the mRNA levels of genes involved in the generation of E-selectin ligands was associated with inferior progression-free survival in the CoMMpass study. In vivo, E-selectin ligand-enriched cells induced a more aggressive disease and were completely insensitive to Bortezomib. Importantly, this resistance could be reverted by co-administration of GMI-1271, a specific glycomimetic antagonist of E-selectin. Finally, we report that E-selectin ligand-bearing cells are present in primary MM samples from BM and peripheral blood with a higher proportion seen in relapsed patients. This study provides a rationale for targeting E-selectin receptor/ligand interactions to overcome MM metastasis and chemoresistance.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Natoni A, Smith TAG, Keane N, et al. E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271. Leukemia. 2017. PMID: 28439107. doi:10.1038/leu.2017.123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。